The estimated Net Worth of John A. Fallon is at least $1.65 Million dollars as of 21 May 2021. John Fallon owns over 5,822 units of AMAG Pharmaceuticals stock worth over $508,000 and over the last 12 years he sold AMAG stock worth over $896,575. In addition, he makes $249,986 as Independent Director at AMAG Pharmaceuticals.
John has made over 11 trades of the AMAG Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 5,822 units of AMAG stock worth $210,174 on 21 May 2021.
The largest trade he's ever made was exercising 14,525 units of AMAG Pharmaceuticals stock on 15 November 2019 worth over $378,086. On average, John trades about 1,532 units every 48 days since 2012. As of 21 May 2021 he still owns at least 20,320 units of AMAG Pharmaceuticals stock.
You can see the complete history of John Fallon stock trades at the bottom of the page.
Dr. John A. Fallon M.D. serves as Independent Director of the Company. From 2004 until January 2016, Dr. Fallon served as Senior Vice President and Chief Physician Executive at Blue Cross & Blue Shield of Massachusetts (“BCBS”). Prior to his role at BCBS, Dr. Fallon served as Chief Executive Officer for clinical affairs at the State University of New York Downstate Medical Center, including University Hospital of Brooklyn and the clinical faculty practice plan. His professional experience also includes the Partners Healthcare System, where he was chairman of the physician network. Dr. Fallon was also the founder and Chief Executive Officer of North Shore Health System, a large physician-hospital organization in Massachusetts. He has served on the Board of Directors of Insulet Corporation, a public medical devices company, since 2012 and as the lead independent director from February 2015 to August 2016 and currently serves as the Chair of the Nominating, Governance and Risk Committee. In addition, Dr. Fallon has been a member of the Board of Directors of Exact Sciences Corporation, a public molecular diagnostics company, since January 2016 where he is also a member of the Audit Committee and Nominating and Governance Committee. Dr. Fallon has also served on the Board of Directors of Collegium Pharmaceutical Inc., a public pharmaceutical company, since June 2016 where he is also a member of the Audit Committee and the Nominating and Governance Committee. Dr. Fallon also serves on NEHI (Network for Excellence in Health Innovation) (Chair), a non-profit board. Dr. Fallon practiced internal medicine for more than 20 years, fulfilled his residency at Boston City Hospital, is Board Certified in Internal Medicine and is a fellow of the American College of Physicians. He received a B.A. in chemistry from the College of the Holy Cross, an M.B.A from the University of South Florida and a medical degree from Tufts University School of Medicine.
As the Independent Director of AMAG Pharmaceuticals, the total compensation of John Fallon at AMAG Pharmaceuticals is $249,986. There are 6 executives at AMAG Pharmaceuticals getting paid more, with Joseph Vittiglio having the highest compensation of $1,411,860.
John Fallon is 72, he's been the Independent Director of AMAG Pharmaceuticals since 2014. There are 1 older and 11 younger executives at AMAG Pharmaceuticals. The oldest executive at AMAG Pharmaceuticals, Inc. is Davey Scoon, 73, who is the Independent Director.
John's mailing address filed with the SEC is C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA, 02072.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C...., and Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: